Bespak, a division of Consort Medical, has received a contract to develop a nasal drug delivery device.
Bespak develops drug delivery devices with a focus on respiratory, autoinjectors and opthalmic markets.
Consort Medical CEO Jon Glenn said with programmes in autoinjectors, Point of Care diagnostics and now nasal applications, Bespak is developing a broad suite of products in new growth markets, de-risking the portfolio.
Bespak Respiratory’s device portfolio includes Medical Check Valves, Valves & Actuators, Dose Counting Actuators and Customer Devices.
The company’s Injectables’ device technology portfolio includes single-use, disposable auto injectors and reusable needle-free jet injectors.